This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pletz, M. W. R.
Right arrow Articles by Lode, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pletz, M. W. R.
Right arrow Articles by Lode, H.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, March 2004, p. 780-782, Vol. 48, No. 3
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.3.780-782.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

Early Bactericidal Activity of Moxifloxacin in Treatment of Pulmonary Tuberculosis: a Prospective, Randomized Study

Mathias W. R. Pletz,1* Andres De Roux,1 Andreas Roth,2 Karl-Heinz Neumann,1 Harald Mauch,2 and Hartmut Lode1

Department of Chest and Infectious Diseases, City Hospital Emil von Behring/Chest Hospital Heckeshorn,1 Institute of Microbiology, City Hospital Emil von Behring, Freie Universität Berlin, 14195 Berlin, Germany2

Received 18 August 2003/ Returned for modification 14 October 2003/ Accepted 11 November 2003

Moxifloxacin is the most active fluoroquinolone against Mycobacterium tuberculosis in vitro. However, data about the efficacy in patients are not available. We enrolled 17 patients with tuberculosis in a prospective, randomized study. After 5 days of monotherapy with either moxifloxacin or isoniazid, we detected significant decreases in mean CFU per milliliter in sputum in both groups. The calculated early bactericidal activities for isoniazid and moxifloxacin were 0.209 and 0.273 log10 CFU per ml of sputum per day, respectively. According to the data from our study, moxifloxacin exhibits an early bactericidal activity that is comparable to that of isoniazid.

* Corresponding author. Present address: Department of International Health, Rollins School of Public Health, Emory University, 1518 Clifton Rd., Atlanta, GA 30322. Phone: (404) 727-3984. Fax: (404) 712-8419. E-mail: mpletz{at}sph.emory.edu.

Antimicrobial Agents and Chemotherapy, March 2004, p. 780-782, Vol. 48, No. 3
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.3.780-782.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • van den Boogaard, J., Kibiki, G. S., Kisanga, E. R., Boeree, M. J., Aarnoutse, R. E. (2009). New Drugs against Tuberculosis: Problems, Progress, and Evaluation of Agents in Clinical Development. Antimicrob. Agents Chemother. 53: 849-862 [Full Text]  
  • Upton, A., Woodhouse, A., Vaughan, R., Newton, S., Ellis-Pegler, R. (2009). Evolution of Central Nervous System Multidrug-Resistant Mycobacterium tuberculosis and Late Relapse of Cryptic Prosthetic Hip Joint Tuberculosis: Complications during Treatment of Disseminated Isoniazid-Resistant Tuberculosis in an Immunocompromised Host. J. Clin. Microbiol. 47: 507-510 [Abstract] [Full Text]  
  • Pardillo, F. E. F., Burgos, J., Fajardo, T. T., Cruz, E. D., Abalos, R. M., Paredes, R. M. D., Andaya, C. E. S., Gelber, R. H. (2008). Powerful Bactericidal Activity of Moxifloxacin in Human Leprosy. Antimicrob. Agents Chemother. 52: 3113-3117 [Abstract] [Full Text]  
  • Burman, W. J., Goldberg, S., Johnson, J. L., Muzanye, G., Engle, M., Mosher, A. W., Choudhri, S., Daley, C. L., Munsiff, S. S., Zhao, Z., Vernon, A., Chaisson, R. E., and the Tuberculosis Trials Consortium, (2006). Moxifloxacin versus Ethambutol in the First 2 Months of Treatment for Pulmonary Tuberculosis. Am. J. Respir. Crit. Care Med. 174: 331-338 [Abstract] [Full Text]  
  • Gillespie, S. H., Gosling, R. D., Uiso, L., Sam, N. E., Kanduma, E. G., McHugh, T. D. (2005). Early bactericidal activity of a moxifloxacin and isoniazid combination in smear-positive pulmonary tuberculosis. J Antimicrob Chemother 56: 1169-1171 [Abstract] [Full Text]  
  • Weber, J. T. (2005). Appropriate Use of Antimicrobial Drugs: A Better Prescription Is Needed. JAMA 294: 2354-2356 [Full Text]  
  • Marra, F., Marra, C. A., Moadebi, S., Shi, P., Elwood, R. K., Stark, G., FitzGerald, J. M. (2005). Levofloxacin Treatment of Active Tuberculosis and the Risk of Adverse Events. Chest 128: 1406-1413 [Abstract] [Full Text]  
  • Gumbo, T., Louie, A., Deziel, M. R., Drusano, G. L. (2005). Pharmacodynamic Evidence that Ciprofloxacin Failure against Tuberculosis Is Not Due to Poor Microbial Kill but to Rapid Emergence of Resistance. Antimicrob. Agents Chemother. 49: 3178-3181 [Abstract] [Full Text]  
  • Nuermberger, E. L., Yoshimatsu, T., Tyagi, S., Williams, K., Rosenthal, I., O'Brien, R. J., Vernon, A. A., Chaisson, R. E., Bishai, W. R., Grosset, J. H. (2004). Moxifloxacin-containing Regimens of Reduced Duration Produce a Stable Cure in Murine Tuberculosis. Am. J. Respir. Crit. Care Med. 170: 1131-1134 [Abstract] [Full Text]  
  • Gosling, R., Gillespie, S., Pletz, M. W. R., Lode, H. (2004). Moxifloxacin Treatment of Tuberculosis. Antimicrob. Agents Chemother. 48: 3642-3643 [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»